NervGen Pharma Announces Proposed Amendment to Warrants @nervgenp #Chemicals #Pharmaceutical #Biotechnology #HealthCare #Medical #Pharmaceuticals #OTC #OTCMarkets #OTCStocks #SmallCaps #TSXV #Investing
Vancouver, British Columbia--(Newsfile Corp. - December 12, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF) ("NervGen" or the "Company"), a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and other traumatic and neurologic disorders, today announced that the Company intends to amend 5,075,000 common share purchase warrants (the "2022 Warrants") that were issued pursuant to a private placement of units that...
http://dlvr.it/TPp4Cl
http://dlvr.it/TPp4Cl
Comments
Post a Comment